Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Granulocyte-stimulating factor and severe aplastic anemia: a survey by the European Group for Blood and Marrow Transplantation (EBMT)

Socie, Gerard ; Mary, Jean-Yves ; Schrezenmeier, Hubert ; Marsh, Judith ; Bacigalupo, Andrea ; Locasciulli, Anna ; Fuehrer, Monica ; Békássy, Albert LU ; Tichelli, Andre and Passweg, Jakob (2007) In Blood 109(7). p.2794-2796
Abstract
Previous studies suggested a link between the use of G-CSF and increased incidence of myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) after immunosuppressive therapy (IST) for severe aplastic anemia (SAA). This European survey included 840 patients who received a first-line IST with (43%) or without (57%) G-CSF. The incidences of MDS/AML in patients who did or did not receive G-CSF were 10.9% and 5.8%, respectively. A significantly higher hazard (1.9) of MDS/AML was associated with use of G-CSF. Relapse of aplastic anemia was not associated with a worse outcome in patients who did not receive G-CSIF as first therapy, whereas relapse was associated with a significantly worse outcome in those patients who received G-CSF.... (More)
Previous studies suggested a link between the use of G-CSF and increased incidence of myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) after immunosuppressive therapy (IST) for severe aplastic anemia (SAA). This European survey included 840 patients who received a first-line IST with (43%) or without (57%) G-CSF. The incidences of MDS/AML in patients who did or did not receive G-CSF were 10.9% and 5.8%, respectively. A significantly higher hazard (1.9) of MDS/AML was associated with use of G-CSF. Relapse of aplastic anemia was not associated with a worse outcome in patients who did not receive G-CSIF as first therapy, whereas relapse was associated with a significantly worse outcome in those patients who received G-CSF. These results emphasize the necessity of the current European randomized trial comparing IST with or without G-CSF and to alert physicians that adding G-CSIF to IST is currently not standard treatment for SAA. (Less)
Please use this url to cite or link to this publication:
author
; ; ; ; ; ; ; ; and
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Blood
volume
109
issue
7
pages
2794 - 2796
publisher
American Society of Hematology
external identifiers
  • wos:000245639000028
  • scopus:33947594348
  • pmid:17110459
ISSN
1528-0020
DOI
10.1182/blood-2006-07-034272
language
English
LU publication?
yes
id
a0825b9c-a656-41e6-aa6c-4e70f46b2885 (old id 666560)
date added to LUP
2016-04-01 12:36:54
date last changed
2022-02-19 00:54:41
@article{a0825b9c-a656-41e6-aa6c-4e70f46b2885,
  abstract     = {{Previous studies suggested a link between the use of G-CSF and increased incidence of myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) after immunosuppressive therapy (IST) for severe aplastic anemia (SAA). This European survey included 840 patients who received a first-line IST with (43%) or without (57%) G-CSF. The incidences of MDS/AML in patients who did or did not receive G-CSF were 10.9% and 5.8%, respectively. A significantly higher hazard (1.9) of MDS/AML was associated with use of G-CSF. Relapse of aplastic anemia was not associated with a worse outcome in patients who did not receive G-CSIF as first therapy, whereas relapse was associated with a significantly worse outcome in those patients who received G-CSF. These results emphasize the necessity of the current European randomized trial comparing IST with or without G-CSF and to alert physicians that adding G-CSIF to IST is currently not standard treatment for SAA.}},
  author       = {{Socie, Gerard and Mary, Jean-Yves and Schrezenmeier, Hubert and Marsh, Judith and Bacigalupo, Andrea and Locasciulli, Anna and Fuehrer, Monica and Békássy, Albert and Tichelli, Andre and Passweg, Jakob}},
  issn         = {{1528-0020}},
  language     = {{eng}},
  number       = {{7}},
  pages        = {{2794--2796}},
  publisher    = {{American Society of Hematology}},
  series       = {{Blood}},
  title        = {{Granulocyte-stimulating factor and severe aplastic anemia: a survey by the European Group for Blood and Marrow Transplantation (EBMT)}},
  url          = {{http://dx.doi.org/10.1182/blood-2006-07-034272}},
  doi          = {{10.1182/blood-2006-07-034272}},
  volume       = {{109}},
  year         = {{2007}},
}